Fibrocell Science Inc (FCSC) Raised to “Hold” at Zacks Investment Research

Zacks Investment Research upgraded shares of Fibrocell Science Inc (NASDAQ:FCSC) from a sell rating to a hold rating in a research report sent to investors on Tuesday morning.

According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “

Several other research analysts also recently commented on the stock. HC Wainwright reaffirmed a buy rating and issued a $7.60 price target on shares of Fibrocell Science in a research note on Thursday, October 5th. Canaccord Genuity reaffirmed a buy rating and issued a $7.00 price target (up previously from $3.00) on shares of Fibrocell Science in a research note on Monday, September 11th. Finally, ValuEngine downgraded shares of Fibrocell Science from a sell rating to a strong sell rating in a research report on Wednesday, September 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of Hold and an average price target of $5.21.

Fibrocell Science (NASDAQ:FCSC) last posted its quarterly earnings results on Wednesday, August 9th. The company reported ($0.31) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.31).

WARNING: “Fibrocell Science Inc (FCSC) Raised to “Hold” at Zacks Investment Research” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://sportsperspectives.com/2017/10/13/fibrocell-science-inc-fcsc-raised-to-hold-at-zacks-investment-research.html.

An institutional investor recently raised its position in Fibrocell Science stock. Parametric Portfolio Associates LLC raised its holdings in shares of Fibrocell Science Inc (NASDAQ:FCSC) by 264.0% during the second quarter, according to its most recent filing with the SEC. The firm owned 48,259 shares of the company’s stock after purchasing an additional 35,000 shares during the period. Parametric Portfolio Associates LLC owned 0.33% of Fibrocell Science worth $194,000 at the end of the most recent reporting period. 54.70% of the stock is owned by institutional investors.

Fibrocell Science Company Profile

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

Get a free copy of the Zacks research report on Fibrocell Science (FCSC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply